| Katrina Lewellyn, | |
|
2976 Triverton Pike Dr # 207, Fitchburg, WI 53711-5840 | |
| (608) 448-8915 | |
| Not Available |
| Full Name | Katrina Lewellyn |
|---|---|
| Gender | Female |
| Speciality | Counselor - Professional |
| Location | 2976 Triverton Pike Dr # 207, Fitchburg, Wisconsin |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144004292 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YP2500X | Counselor - Professional | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Katrina Lewellyn, 229 Swanton Rd Apt 1, Madison, WI 53714-1967 Ph: (608) 448-8915 | Katrina Lewellyn, 2976 Triverton Pike Dr # 207, Fitchburg, WI 53711-5840 Ph: (608) 448-8915 |
News Archive
According to the U.S. Food and Drug Administration, liver problems linked to the attention deficit drug Cylert and other generic versions of the drug make it too dangerous for the U.S. market.
The "Treatment for Adolescents with Depression Study" (TADS), reported in this week's Journal of the American Medical Association, is the first multi- center, randomized clinical effectiveness trial to review a combination of treatments for the types of adolescent depression likely to be treated in routine community-based practice settings.
Beyond the legal challenges, a major new hurdle is emerging for the health care reform law. Recent studies show that the major players in the health care marketplace - insurers, hospitals and physician practices - are consolidating, which increases the likelihood they will collude on prices charged to employers and to consumers and defeat cost control measures in the law.
Global regenerative medicine company, Mesoblast Limited, (ASX: MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor™ in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor™ is an allogeneic, or "off-the-shelf", adult stem cell product derived from Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) platform technology which is being developed for use in a range of cardiovascular diseases including congestive heart failure, chronic angina, and heart attacks (acute myocardial infarction).
› Verified 6 days ago
Katherine Cousin, M.A., LPC, LMHC Counselor Medicare: Not Enrolled in Medicare Practice Location: 2935 S Fish Hatchery Rd Ste 334, Fitchburg, WI 53711 Phone: 608-469-6271 | |
Lisa Nj Hoeme, MS, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 2875 Fish Hatchery Rd, Fitchburg, WI 53713 Phone: 608-204-6242 Fax: 608-204-6249 | |
Frederick Harris, Counselor Medicare: Not Enrolled in Medicare Practice Location: 5930 Seminole Centre Ct Ste C, Fitchburg, WI 53711 Phone: 608-630-8889 Fax: 608-200-7268 | |
Jessica Marie-lynch Abegglen, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 3028 Edenberry St, Fitchburg, WI 53711 Phone: 608-445-6064 | |
Catherine Kirner, Counselor Medicare: Not Enrolled in Medicare Practice Location: 2940 Chapel Valley Rd Ste 2, Fitchburg, WI 53711 Phone: 608-709-9672 Fax: 608-416-1535 | |
Liza Hahn, LPC-IT Counselor Medicare: Not Enrolled in Medicare Practice Location: 2961 Yarmouth Greenway Dr Ste 2, Fitchburg, WI 53711 Phone: 608-709-9672 Fax: 608-416-1535 |